Connection
David Simpson to Genomics
This is a "connection" page, showing publications David Simpson has written about Genomics.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.035 |
|
|
|
-
Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu E, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022 06; 63(6):1375-1386.
Score: 0.035